Cytokinetics (CYTK) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $63.31 --0%
EPS Growth %: +43.1%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
TFS, PBNK, FNRN, More
EPS Growth %: +43.1%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
TFS, PBNK, FNRN, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.50), $0.13 better than the analyst estimate of ($1.63). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $17.09 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TFS Financial (TFSL) Reports In-Line Q4 EPS
- Citi cuts Stryker price target to $315 from $360
- Pinnacle Bank (PBNK) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
